Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...

Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in ...

Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer Twenty-eight patients underwent apheresis and received CAR T cells. Sixteen and 12 patients ...

CD19, a B-cell surface protein ... antibody affinity measurement and detection of anti-CD19 CAR expression. The high activity of such proteins has been confirmed by ELISA, SPR and flow cytometry ...

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The high-affinity CD19 proteins from ACROBiosystems exhibit the potential to effectively detect the anti-CD19 CAR expression on the surface of transduced T cells. These proteins have been ...

More than 13 years after its initial FDA approval, Pfizer’s blood cancer drug Adcetris has nabbed another regulatory green ...

Of note, unlike other CAR T-cell therapies, the CD19-directed genetically modified ... have relapsed or refractory ALL after ...

The EC's decision was based on results from a Phase III trial of Blincyto with multiphase consolidation chemotherapy.

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...